NASDAQ:AKBA

Akebia Therapeutics Stock Predictions

etoro logo Buy AKBA
*Your capital is at risk
$0.97
+0.0333 (+3.56%)
At Close: Jun 03, 2026
Currently predicting for Thu, 4 Jun 2026

AKBA Prediction Chart

AKBA Predictions History

Latest community submissions for AKBA.
Predictor Target Session Target Price Result Direction Accuracy Score
Sep 12, 2025 $3.03 +1.30% $2.95 X 97.33% 0
Sep 12, 2025 $7.50 +155.97% Unrealistic Excluded from avg $2.95 V 0.00% 0
Aug 28, 2025 $3.08 +2.27% $3.13 V 98.35% 1
Aug 28, 2025 $3.05 +1.42% $3.13 V 97.53% 1
Aug 28, 2025 Bullish $3.13 V 1
Aug 18, 2025 $3.33 +2.35% $3.11 X 93.04% 0
Aug 18, 2025 $3.30 +1.47% $3.11 X 93.96% 0
Aug 18, 2025 $4.00 +23.08% $3.11 X 71.38% 0
Aug 13, 2025 $3.37 +1.61% $3.32 X 98.39% 0
ir1998ri ir1998ri Amateur
Aug 13, 2025 Bearish $3.32 X 0
Click to get the best stock tips daily for free!
Forecast Desk

Request A 3-Month Forecast

Ask an approved predictor to map the next 66 trading days for AKBA with a full price path, not just a one-day call.
  • Price path
  • Approved predictor
  • 3-month horizon
ABOUT AKEBIA THERAPEUTICS
Akebia Therapeutics
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE